Skip to main content

Advertisement

SpringerLink
Log in

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units

  • Letter
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388

    Article  CAS  PubMed  Google Scholar 

  2. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394

    Article  CAS  PubMed  Google Scholar 

  3. Ahn HK, Jeon K, Yoo H, Han B, Lee SJ, Park H, Lee MJ, Ha SY, Han JH, Sun JM, Ahn JS, Ahn MJ, Park K (2013) Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer. J Thorac Oncol 8:250–253

    Article  CAS  PubMed  Google Scholar 

  4. van Geffen WH, Hiltermann TJ, Groen HJ (2013) Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation. J Thorac Oncol 8:e1–e2

    Article  PubMed  Google Scholar 

  5. Toffart AC, Minet C, Raynard B, Schwebel C, Hamidfar-Roy R, Diab S, Quetant S, Moro-Sibilot D, Azoulay E, Timsit JF (2011) Use of intensive care in patients with nonresectable lung cancer. Chest 139:101–108

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

ACT: Roche, Boehringer Ingelheim; XD: Boehringer Ingelheim; CAV: Roche, AstraZenea, Boehringer Ingelheim, Pfizer; BM: Roche, AstraZenea, Boehringer Ingelheim, Pfizer; PF: Roche, AstraZenea, Boehringer Ingelheim, Pfizer; DMS: Roche, AstraZenea, Boehringer Ingelheim, Pfizer; NG, CC, MD, AP and JFT declared that they have no competing interests.

Author information

Authors and Affiliations

  1. Grenoble University 1 U 823, A Bonniot Institute, J Fourier University, Rond-point de la Chantourne, 38706, La Tronche Cedex, France

    Anne-Claire Toffart & Denis Moro-Sibilot

  2. Thoracic Oncology Unit, Pôle Thorax et Vaisseaux, Centre Hospitalier Universitaire A Michallon, BP217, 38043, Grenoble cedex 9, France

    Anne-Claire Toffart, Michaël Duruisseaux & Denis Moro-Sibilot

  3. Thoracic Oncology Department, Centre Hospitalier Régional Universitaire, Bd Professeur J Leclercq, 59037, Lille, France

    Xavier Dhalluin

  4. Respiratory Medicine Service, Hôpital Louis Pradel, Hospices Civils de Lyon, 28 avenue doyen Lépine, 69677, Lyon-Bron cedex, France

    Nicolas Girard

  5. UMR 754, Université Claude Bernard Lyon 1, 50 avenue Tony Garnier, 69007, Lyon, France

    Nicolas Girard

  6. Respiratory Medicine Department, Centre Hospitalier Intercommunal Créteil, 40 avenue de Verdun, 94010, Créteil, France

    Christos Chouaid

  7. Respiratory Medicine Department, Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer, 54 rue Sainte Claire Deville (CS 31412), 83056, Toulon Cedex, France

    Clarisse Audigier-Valette

  8. GRC University Paris 6 Pierre et Marie Curie Theranoscan, Hôpital Tenon, APHP, 4 rue Chine, 75020, Paris, France

    Michaël Duruisseaux

  9. Respiratory Medicine Department, Centre Hospitalier Régional Universitaire, Hôpital Civil de Strasbourg, 1 place de l’hôpital, 67000, Strasbourg, France

    Bertrand Mennecier

  10. Medical and Surgical Intensive Care Unit, Pôle Thorax Voies aériennes, Groupe hospitalier des Hôpitaux Universitaires de l’Est Parisien, 4 rue Chine, 75020, Paris, France

    Antoine Parrot

  11. Department of Medical Oncology, Institut de Cancérologie Lucien Neuwirth, 42271, Saint-Priest en Jarez, France

    Pierre Fournel

  12. Medical and Infectious Diseases ICU, AP-HP, Hôpital Bichat, 46 rue Henri Huchard, 75018, Paris, France

    Jean-François Timsit

  13. Paris Diderot University, IAME, UMR 1137, Sorbonne Paris Cité, 75018, Paris, France

    Jean-François Timsit

Authors
  1. Anne-Claire Toffart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xavier Dhalluin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicolas Girard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christos Chouaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Clarisse Audigier-Valette
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michaël Duruisseaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bertrand Mennecier
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Antoine Parrot
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Pierre Fournel
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Denis Moro-Sibilot
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jean-François Timsit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne-Claire Toffart.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toffart, AC., Dhalluin, X., Girard, N. et al. Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units. Intensive Care Med 41, 164–165 (2015). https://doi.org/10.1007/s00134-014-3535-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-014-3535-x

Keywords

Search

Navigation